TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SynAct Pharma AB ( (SE:SYNACT) ) has shared an announcement.
SynAct Pharma AB announced that its board and executive management have entered into lock-up agreements for their shares, which account for 6.9% of the company’s votes and capital, until December 31, 2025. This move underscores the leadership’s commitment to the company’s future development and stability, potentially reassuring stakeholders about the company’s strategic direction and long-term goals.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company offers a broad portfolio of oral and injectable selective melanocortin agonists aimed at treating autoimmune and inflammatory diseases.
Average Trading Volume: 230,376
Current Market Cap: SEK944.6M
See more data about SYNACT stock on TipRanks’ Stock Analysis page.